학술논문

Patterns of response and acquired resistance to the programmed death‐1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.
Document Type
Article
Source
Dermatologic Therapy. Nov2019, Vol. 32 Issue 6, pN.PAG-N.PAG. 1p.
Subject
*SQUAMOUS cell carcinoma
*PEMBROLIZUMAB
*SKIN cancer
Language
ISSN
1396-0296
Abstract
A 79-year-old man presented with a not operable, previously treated Stage III cutaneous squamous cell carcinoma (cSCC) at our Skin Cancer Unit. At time of the third cycle, a regain of the tumor volume was noticed (Figure c), which was considered as pseudo-progression and patient continued on treatment for further three cycles showing initially partial response, particularly at the periphery of the tumor (Figure d). Irrespective of the treatment, the tumor progressed rapidly and treatment was permanently stopped (Figure f). [Extracted from the article]